Molecular markers of prostate cancer outcome
- 30 April 2005
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 41 (6), 858-887
- https://doi.org/10.1016/j.ejca.2004.12.035
Abstract
No abstract availableThis publication has 94 references indexed in Scilit:
- Lower levels of nuclear β‐catenin predict for a poorer prognosis in localized prostate cancerInternational Journal of Cancer, 2004
- Overexpression of cyclin D1 is rare in human prostate carcinomaThe Prostate, 1999
- Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumorsCancer, 1998
- Molecular Cloning, Differential Expression, and Chromosomal Localization of HumanFrizzled-1, Frizzled-2,andFrizzled-7Biochemical and Biophysical Research Communications, 1998
- Vascular Endothelial Growth Factor Is Up-Regulatedin Vitroandin Vivoby AndrogensBiochemical and Biophysical Research Communications, 1998
- Molecular Analysis of the INK4 Family of Genes in Prostate CarcinomasJournal of Urology, 1997
- Mutations of the p16 gene product are rare in prostate cancerThe Prostate, 1997
- Infrequent RAS oncogene mutations in human prostate cancerThe Prostate, 1992
- Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parametersThe Prostate, 1992
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990